Chemokines and their receptors play important roles in various aspects of tumoral processes, and evidence was provided for their critical involvement in determining the metastatic destination of tumor cells. Here, we analyzed in vitro and in vivo, how CCR6 expression could alter the behavior of Lewis lung carcinoma (LLC) cells, which were shown to express low levels of the CCR6 ligand, CCL20 (LARC), both in vitro and in vivo. The expression of CCR6 significantly decreased the number of metastases in immunocompetent C57BL/6 mice, without affecting the tumor-forming ability of LLC cells. This was correlated with a decrease in clonogenicity in soft and hard agar, and with increased adhesion to type-IV collagen. These two observations made in basal conditions were enhanced when CCL20 was added to the assay medium. Thus, expression of CCR6 in tumor cells, associated with the local production of CCL20, decreased the metastatic potential of the LLC line. We propose a model, in which the expression of a chemokine receptor in tumor cells can act as a metastasis-suppressor, or a metastasis-promoting factor, according to the expression, or the absence of expression of the cognate ligand(s) in the tumor.
Introduction
Chemokines and their receptors constitute the key elements regulating the trafficking of white blood cells in basal and inflammatory conditions. [1] [2] [3] They play, therefore, a major role in the initiation and the control of inflammatory and immune responses, including in the context of tumorigenesis. Most cancers originating from a variety of tissues were shown to express chemokines and/ or chemokine receptors. 1, 4 The chemokine system plays ambivalent roles in various aspects of tumoral processes, and evidence was provided for their critical involvement in determining the metastatic destination of tumor cells. [5] [6] [7] CCR6 is the unique receptor for the chemokine CCL20, also referred to as liver and activation-regulated chemokine (LARC), macrophage inflammatory protein 3a or Exodus-1.
8 CCR6 and CCL20 were described to be involved in tumoral and metastatic processes. CCL20 expression was reported in a variety of human tumors, including pancreatic carcinoma, oral squamous cell carcinoma and glioma, [9] [10] [11] as well as in human tumoral cell lines originating from melanoma, lung and colon carcinomas, osteosarcoma, lymphoma and leukemia. 12, 13 A melanoma cell line was reported to overexpress CCL20 when cultured in 3D spheroids instead of bidimensional monolayers.
14 Coexpression of CCL20 and CCR6 was described in tumor cells of human pancreatic carcinomas and in human pancreatic and hepatic cancer cell lines, while CCL20 was also found in stromal cells, suggesting the existence of autocrine and paracrine loops involving this system. 9,15 CCL20 was described to promote invasion of a type-IV collagen matrix by tumor cells, in a CCR6-dependent manner. 15 CCR6 also appeared to be slightly overexpressed in breast cancer cells. 5 A recent report has shown that while primary squamous cell carcinoma of the head and neck frequently expressed CCR6, the expression of the receptor was consistently downregulated in metastatic tumors, in contrast to CCR7 that was usually upregulated in the same set of samples. 16 These observations suggest that CCR6 downregulation might be a selected feature in cells acquiring the ability to emigrate from peripheral mucosal sites in which CCL20 is expressed. Similarly, CCL20 was found to be downregulated together with other genes in the metastatic subpopulations of a human pulmonary adenocarcinoma cell line. 17 On the other hand, CCL20 was reported to favor the metastatic spread of human colorectal cancer to the liver 18, 19 and to promote hepatic metastases in a mouse plasmacytoma model. 20 To investigate the role played by CCL20 and CCR6 in antitumor immune responses, and as models for gene therapy approaches, the consequences of the expression of CCL20 in tumor models were investigated by several groups. [21] [22] [23] From these studies, it appears that as for other chemokines, CCL20 expression results in the recruitment of CCR6-expressing cells, but the outcome depends on other factors related to the tumoral cell type involved and other aspects of the tumoral microenvironment. The consequences of CCR6 expression were by contrast not investigated experimentally. We have therefore tested the phenotypic changes resulting from CCR6 expression in the Lewis lung carcinoma (LLC) cell line, which express low levels of CCL20 naturally, thus exploring the role of autocrine loops proposed for human tumors.
In this work, we have confirmed the observation that CCR6 and/or CCL20 are expressed in a variety of human tumors and tumor cell lines. We have next addressed whether CCR6 expression could modify either the growth properties of primary tumors, or the generation of secondary metastases in the mouse LLC model. We found that CCR6 expression did not significantly modify tumor growth at the primary site of injection. However, the number of lung metastases in animals grafted with CCR6-expressing cells was significantly decreased. The reduced metastatic potential could be correlated with decreased clonogenicity in soft and hard agar, and with increased adhesiveness to type-IV collagen.
Materials and methods

Cell lines and culture conditions
The LLC cell line was maintained in Dulbecco's modified Eagle's medium (DMEM) medium supplemented with 10% fetal calf serum, 100 units/ml penicillin and 100 mg/ ml streptomycin (Invitrogen, Carlsbad, CA). The neomycin-resistant CCR6 transfectants were maintained in DMEM containing 1000 mg/ml G418 (Invitrogen).
Cloning and expression of mouse CCR6
The coding sequence of mouse CCR6 (accession number AB016031) was amplified by reverse transcription (RT)-PCR from total mouse spleen RNA using 5 0 -CATTG GATCCACCATGAATTTCCACAGAGTCC-3 0 as sense and 5
0 -TGCTTCTAGATTACATGGTAAAGGACGAT GC-3 0 as antisense primers. The amplified DNA fragment was cloned into the bicistronic eukaryotic expression vector pEFIN3 and sequenced on both strands. The resulting pEFIN3-CCR6 plasmid was transfected into LLC cells using GeneJammer (Stratagene, La Jolla, CA) according to the manufacturer's instructions. The empty pEFIN3 vector was also transfected as a control. G418-resistant cells were grown in selective medium, and clonal cell lines were derived by limiting dilution.
RT-PCR
RT-PCR experiments were carried out using the One-
Step RT-PCR kit as described by the manufacturer (Invitrogen). Lakes, NJ) was used for data acquisition and analysis (10 000 events per sample). For assaying CCR6 internalization, the cells were incubated with recombinant mouse CCL20 (10, 100 or 500 nM) for various time periods at 371C.
CCL20 ELISA
To measure CCL20 secretion by LLC cells, the clones were cultured in DMEM containing 10% fetal calf serum for 72 h. The culture supernatant was collected, concentrated by ultrafiltration (Centricon, cutoff 3 kDa, Millipore, Billerica, MA) and measured by enzyme-linked immunosorbent assay (ELISA) as described by the manufacturer (Duoset mouse CCL20, R&D Systems).
Intracellular calcium release assay
For the measurement of intracellular calcium mobilization, CCR6-expressing LLC cells, pretreated or not for 16 h with various concentrations of pertussis toxin (0.1-100 ng/ml, Sigma, St Louis, MD, USA), were incubated for 30 min at 371C in Hank's balanced salt medium containing 0.1% bovine serum albumin (BSA), 2.5 mg/ml Fura-2 (Molecular Probes, Carlsbad, CA) and 100 ng/ml F127 (Sigma). The cells were used at a density of 2.10 6 cells/ml and intracellular calcium was measured using a LS50B fluorescence spectrophotometer (Perkin-Elmer Sciences, Waltham, MA).
Chemotaxis assay
A 48-well microchemotaxis chamber (Neuroprobe, Gaithersburg, MD) and 8 mm pore size membranes were used to study the chemotactic response to CCL20, following the manufacturer's instructions. The lower wells were filled with DMEM containing various concentrations (0-10 nM) of CCL20. CCR6-expressing cells /well in DMEM), pretreated or not for 16 h with 100 ng/ml of pertussis toxin, were loaded into the upper wells and allowed to transmigrate for 6 h at 371C. The upper side of the filters was scraped, whereas the cells that traveled across the membrane were stained with DiftQuick and counted under a microscope.
Cell proliferation assay
The percentage of cells present in the S-phase of the cell cycle was determined by bromodeoxyuridine incorporation as previously described. 24 Tumor models Six-to eight-week-old female C57BL/6 mice were purchased from Harlan. All animal experiments were performed according to EU ethical guidelines and were approved by the local ethical committee. For subcutaneous grafting, cells were resuspended at a density of 1 Â 10 7 cells/ml in phosphate-buffered saline (PBS) before injecting 0.1 ml of the cell suspension subcutaneously into the dorsal flanks of syngenic mice (six mice/group). The size of the tumors was measured daily thereafter to assess the growth rate. Mice were killed 4 weeks after injection and the tissues processed as described below. For intravenous injection, cells were resuspended at a density of 25 Â 10 6 cells/ml in PBS and 0.1 ml of the cell suspension was injected into the tail vein (10 mice/group). After 18 days, mice were killed, and the tissues processed as described below.
Tissue processing
Lung and other tissues were collected at the end of each experiment and either fixed in 4% paraformaldehyde for paraffin embedding, or snap frozen for RNA extraction. An index of metastasis was obtained by counting the number of metastasis by light microscopy (Â 40) within five hematoxylin-eosin-stained paraffin sections cut across the left lung or liver left lobe, 200 mm apart.
Clonogenic soft agar assay A layer of complete medium with 0.5% agar was set into six-well plates. A suspension of cells (1 Â 10 3 /ml) in 0.3% agar was overlaid onto the basal layer. A similar experiment was performed using hard agar (0.9%) as an upper layer (5 Â 10 3 cells/ml), as clonal cell growth in these conditions has been shown to be more closely related to the metastatic efficiency as compared to the soft agar assay. The number of colonies was determined 15 days after plating. To test the effect of CCL20 in this assay, 1 ml of complete medium, supplemented or not with 10 nM CCL20, was added on top of the cell containing 0.3% agar layer, immediately after gelling, and this medium was changed twice a week.
Adhesion assay
Adhesion was measured in a 96-well plate assay. Briefly, wells were coated overnight at 41C with mouse laminin, fibronectin or collagen type IV at a concentration of 5 mg/cm 2 . The wells were then rinsed with PBS before incubation with a blocking solution of DMEM:F12 containing 1% BSA for 1 h at 371C. After removing the medium, the wells were rinsed and 5 Â 10 4 cells were dispensed into each well in the presence or not of 10 nM CCL20. Following incubation at 371C for various time periods (5, 15, 30, 45 , 60, 90 and 120 min), the wells were gently washed three times with PBS. The remaining cells were quantified by the MTS bioreduction assay (Promega, Madison, WI), and the percentage of adherent cells was calculated relative to the cell load in each well.
Statistical analysis
Unless indicated, all data represent mean values7s.e.m. calculated from at least three independent experiments. The Mann-Whitney U-test was used to test for the significance level between independent variables. Statistical significance was defined as follows: *Po0.05, **Po0.01 and ***Po0.001.
Results
CCR6 is expressed in human tumors and tumor cell lines
We have investigated the expression of chemokines and chemokine receptors in a set of human tumors, mainly from lung, brain and colon, and we observed the frequent expression of CCR6 and/or CCL20, among other genes of these families (data not shown). These observations are consistent with other reports in the literature, that have described the expression of CCR6 in pancreatic and breast cancer cells. 5, 9 We also tested the presence of CCR6 transcripts in human tumoral cell lines derived from a variety of tumors (lymphomas, colon, liver, stomach, breast, skin, pancreas, prostate cancer), and could demonstrate by RT-PCR, that several of these lines express CCR6 (Figure 1a) , although there was no obvious correlation with the origin of the tumor. A subset of the tumor cell lines also contained CCL20 transcripts, and some expressed both CCR6 and CCL20 (Figure 1a) . Two cell lines, CESS and RF48, were characterized by high levels of CCR6 transcripts (Figure 1a ). Surface expression of CCR6 was confirmed by FACS analysis in both cases ( Figure 1b ) and we could demonstrate that CESS cells respond functionally to human CCL20, resulting in the mobilization of intracellular calcium (data not shown). CCL20 expression was particularly high in the PC3 cell line, and the biological activity of PC3-conditioned medium was confirmed by inducing calcium mobilization in CHO-K1 cells expressing human CCR6 (data not shown). To investigate further the functional role of CCL20 and CCR6 in tumor cell biology, we studied the consequences of CCR6 expression in a mouse tumor model of the LLC. Preliminary experiments had shown that LLC cells expressed low levels of functional CCL20 (see below), allowing to investigate the consequences of an autocrine loop in vivo.
Generation and characterization of mouse tumor cell lines expressing functional mouse CCR6
The full-length mouse CCR6 cDNA was cloned into the pEFIN3 expression vector, transfected into LLC cells, CCR6 and metastasis suppression A Sutherland et al and clonal cell lines expressing the receptor (LLC/CCR6) were established and characterized. Concomitantly, the empty vector was transfected in LLC cells, to generate negative control cell lines (LLC/pEFIN3). Four CCR6-expressing and four control clones were selected for in vitro characterization.
Expression of CCR6 was first studied by FACS analysis. Surface expression of CCR6 could be demonstrated for all four LLC/CCR6 clones, and two LLC/ CCR6 clones (clone 12 and clone 23) expressing moderate levels of CCR6 were selected for further studies in vitro and in vivo in parallel to two control clones (Figure 2a ). As expected, short-term exposure to high concentrations of the receptor agonist (recombinant mouse CCL20, rmCCL20) caused CCR6 internalization, resulting in a dose-and time-dependent decrease in the surface expression of the receptor (Figure 2b) . We investigated the expression of CCL20 in these cell lines as well. As shown in Figures 2c and d, CCL20 transcripts were present at similar levels in all cell lines, while bioactive CCL20 released in the medium was slightly lower for cell lines expressing CCR6, possibly as the result of intracellular trapping or receptor-mediated endocytosis. The functionality of the receptor was also checked by monitoring calcium mobilization in LLC/CCR6 cells (Figure 3) . The response to rmCCL20 was detectable at concentrations as low as 0.1 nM and was dose-dependent up to a maximal response obtained with 10 and 100 nM (Figure 3a) . Complete desensitization to subsequent CCL20 challenge was observed following a first stimulation with 100 nM rmCCL20, while partial desensitization resulted from the stimulation with lower rmCCL20 concentrations (Figure 3b ). The calcium response was not affected by pertussis toxin pretreatment (data not shown), suggesting that CCR6 signaling in LLC cells is partly mediated by the G q family of heterotrimeric G proteins, in addition to the G i family. We finally tested the ability of rmCCL20 to elicit LLC/CCR6 migration in a chemotaxis assay in vitro, using Boyden microchambers with 8 mm pore size CCR6 and metastasis suppression A Sutherland et al membranes. Chemotaxis was obtained for both LLC/ CCR6 clones, with a stronger response observed for clone 12. A typical bell-shaped concentration-action curve was obtained with a maximal effect occurring at the concentration of 0.5 nM rmCCL20 (Figure 3c ). Addition of rmCCL20 to the upper chamber of the setting did not result in increased cell migration (data not shown), demonstrating that the observation constitute actual chemotaxis, and not chemokinesis. Pretreatment of cells with pertussis toxin inhibited the chemotaxis of both clone 23 ( Figure 3d ) and clone 12 (data not shown).
Phenotypic consequences of CCR6 expression in LLC cells
The consequences of CCR6 expression on the phenotype of the cells in vitro and in vivo was investigated, using two LLC/CCR6 clones as compared to two pEFIN3-transfected clones (clone 1 and clone 4), and, in some assays, to the original untransfected LLC cell line. No difference was observed in terms of in vitro proliferation rate, and CCR6 expression did not affect the distribution of cultured cells across the different phases of the cell cycle (data not shown). Moreover, acute or chronic treatment of the cells with rmCCL20 had not effect on these parameters. Table 1 and Figure 4 . CCR6 expression did not significantly modify the growth of the tumor at the primary site (Figure 4a ). By 4 weeks following the graft, the tumor reached a size index in the range of 600-1000 mm 3 for CCR6-expressing and control LLC lines, which is similar to the size obtained with the untransfected parental LLC line itself (not shown). CCR6 transcripts could be detected by RT-PCR in the tumors derived from LLC/CCR6 lines (but not from control LLC lines), demonstrating that the receptor is expressed in vivo (data not shown). Similarly, CCL20 expression was also demonstrated in all tested tumors by RT-PCR (Figure 4c) . Following hematoxylineosin staining, the primary tumors were characterized by a dense mass of fusiform cells, with occasional areas of necrosis. No difference was observed between CCR6-expressing and control tumors (data not shown). No metastases were found, either macroscopically or microscopically in other organs than the lung and liver. However, the number of microscopic lung metastases in animals grafted with LLC/CCR6 cell lines was significantly lower (Po0.05) than in those grafted with control LLC/pEFIN3 lines (Table 1, Figure 4b ), and their size was smaller on average (data not shown). The number of liver metastases was also significantly lower for LLC/ CCR6-grafted mice (3.3 metastases per section across the left lobe of the liver for the LLC/CCR6 group, versus 7.5 for the LLC/pEFIN3 group, Po0.05, data not shown).
To test whether the differences in metastasis number were due to a modification in the ability of the cells to colonize the lung and liver, we injected control or CCR6-expressing LLC cells intravenously, and counted the number of metastases as above. In these conditions, no significant difference was observed (data not shown).
Adhesion and clonogenic properties of LLC/CCR6 cells
To investigate further the mechanisms by which CCR6 expression resulted in a lower metastatic potential of LLC cells, we analyzed the adhesion and clonogenic properties of the LLC/CCR6 and control LLC/pEFIN3 cell lines in culture. A number of reports have demonstrated the correlation between clonogenicity on hard and/or soft agar and metastatic potential. 25, 26 CCR6 expression was effectively correlated with a significantly lower ability (Po0.01) to form colonies in both soft (0.3%) and hard (0.9%) agar (Figures 5a and b) . Treatment of LLC/CCR6 cells with rmCCL20 resulted in a further reduction of their clonogenic properties in soft agar, demonstrating that signaling through the receptor contributes to the observed phenotype (Figure 5c ).
The morphology of cells in standard culture conditions was found to be clearly different between LLC/CCR6 and LLC/pEFIN3 control lines. Wild-type LLC cells are characterized by poor adhesion to the culture plates, a rounded morphology and a tendency to grow as multilayered colonies. Such aspect was observed for the two LLC/pEFIN3 lines, 4 days after plating, as illustrated in Figure 5d . In contrast, both LLC/CCR6 clones exhibited a different phenotype, with spreaded and flattened cells, strongly adherent to the plates, and growing strictly as monolayers. This phenotype suggested increased adhesion to the extracellular matrix, and the kinetics of cell adhesion to culture plates coated with three major components of the matrix (fibronectin, laminin and type-IV collagen) was therefore investigated. LLC/CCR6 and LLC/pEFIN3 control lines behaved similarly in terms of adhesion to fibronectin and laminin substrates (data not shown). However, one of the two LLC/CCR6 clones adhered more efficiently to type-IV collagen-coated plates in basal conditions, while rmCCL20 treatment increased adhesion of both LLC/CCR6 clones to this substrate (Po0.05, Figure 5e ). Overnight pretreatment with rmCCL20 prevented the stimulatory effect of CCL20 on adhesion to type-IV collagen (data not shown). The stimulatory effect of rmCCL20 was not abolished by pertussis toxin pretreatment. No effect of rmCCL20 was observed on the adhesion of control LLC/pEFIN3 clones to any of the tested substrates, or on the adhesion of LLC/CCR6 clones to fibronectin-or laminin-coated plates (data not shown).
The effects of CCR6 expression in in vitro assays were expected to involve the activation of CCR6-dependent intracellular cascades, which might result from the constitutive activity of the receptor, or from its autocrine stimulation by endogenously expressed CCL20. Indeed, both in the soft agar clonogenicity assay and the adhesion assay to type-IV collagen, CCL20 stimulation enhanced the basal phenotypic difference with control LLC/ pEFIN3 clones. No constitutive activity of CCR6 could be demonstrated in a GTPgS assay (data not shown). The moderate expression of the ligand by LLC cells is therefore expected to mediate the basal activation of CCR6 in culture conditions, and its phenotypic consequences.
Discussion
The involvement of chemokines and their receptors in tumoral processes has attracted increasing interest over the past few years, and evidence was given for their critical role in determining the metastatic destination of tumor cells. 5 In this work, we focused on the receptor CCR6 and its ligand CCL20, both expressed in a variety of human tumors as well as in human tumoral cell lines.
5,9-16 CCR6 and CCL20 expression was also observed in our laboratory in a panel of human tumors and human tumoral cell lines, in addition to other chemokine and chemokine receptor genes. We have analyzed here the functional consequences of their expression on the biology of tumors.
We have analyzed how CCR6 expression could alter the behavior of the murine LLC cell line in vitro and in vivo. LLC cells, that express naturally low levels of CCL20, were transfected with the murine CCR6 cDNA 27 and the functionality of the receptor was assessed by analysis of surface expression, intracellular calcium mobilization and chemotaxis assays. The CCR6-expressing LLC cells responded to CCL20 by intracellular calcium mobilization from 0.1 nM concentrations, in a pertussistoxin insensitive manner, in agreement with a dual G q /G i coupling reported previously.
28 CCL20 also induced chemotaxis of LLC/CCR6 cells, demonstrating that the intracellular cascade required for coupling chemokine receptor activation to cell migration is present in LLC cells. Thus, the mouse CCR6 receptor appeared as fully functional in LLC cells in vitro.
We have next analyzed the behavior of LLC/CCR6 cells in vivo in comparison to control cell lines transfected with the empty expression vector. Cells were subcutaneously grafted into the dorsal flank of syngenic mice. CCR6 expression did not significantly modify the tumor growth at the primary site, but the number of metastases was significantly lower in the lung and liver. When the cells were injected intravenously, the number of lung metastases was similar for all cell lines, suggesting that the different behavior of CCR6-expressing cells is due to a reduced ability to leave the primary tumor rather than to colonize distant tissues. The main role of chemokine receptors is to direct the migration of cells expressing them to sites where the ligand is produced, and such role was described in the field of tumorigenesis for tumor cells expressing CXCR4. 5 The reduction of metastatic potential of LLC cells expressing CCR6 was therefore interpreted as the result of local CCL20 production by the tumor cells themselves (and possibly by stromal cells as well), resulting in the retention of the tumor cells at the primary site. To document this further, in vitro changes in cellular behavior were investigated.
The progression of cells toward a metastatic phenotype is often accompanied by increased anchorage-independent growth and decreased requirements for cellsubstratum adhesion. 29 These aspects were analyzed for LLC/CCR6 and control cell lines. The morphological changes observed for LLC/CCR6 cells suggested modifications of the cell-matrix adhesion properties, which were confirmed by the observation that these cells adhered more readily to type-IV collagen (but not to fibronectin or laminin). The fact that rmCCL20 treatment stimulated further adhesion of LLC/CCR6 cells to collagen demonstrated clearly the involvement of CCR6 in this process. Adhesion to type-IV collagen is mediated by integrins, particularly b 1 chains associated with a (1, 2, 3, 5) subunits. 30 As demonstrated for other chemokine receptors, activation of CCR6 results in the reorganization of the actin cytoskeleton and the activation of integrins. [31] [32] [33] The increased adhesiveness mediated by CCR6 could therefore be replaced into the general frame of leukocyte diapedesis, in which triggering by chemokines induces the firm arrest of lymphocytes and other cell types onto endothelial cells via integrins activation. CCL20 itself has been demonstrated to promote the arrest of B and T lymphocytes under physiologic flow conditions, 31, 32, 34 by promoting their adhesiveness to activated endothelial cells. 33 Anchorage-independent growth of LLC/CCR6 cells was studied in a clonogenic assay. In agreement with previous reports demonstrating the good correlation between clonogenicity on hard and/or soft agar and the metastatic potential, 25, 26 CCR6 transfectants formed significantly fewer colonies than control cells. Moreover, CCL20 treatment resulted in a further decrease of clonogenicity of LLC/CCR6 cells in soft agar. Anchorage-independent growth of tumors cells has been attributed to an increase in their independence from growth-regulatory mechanisms. 25 Conversely, the reduction of anchorage-independent growth of CCR6-expressing LLC cells can be viewed as an enhanced dependence to growth-regulatory mechanisms, resulting in a reduction of the aggressive phenotype.
The consequences of CCR6 expression in the absence of added CCL20 suggest a basal activity of the receptor in LLC cells. Constitutive activity could not be demonstrated in a GTPgS binding assay on cell membranes. The low expression of CCL20 by LLC cells explains therefore likely the basal activation of CCR6. The fact that CCL20 addition to the culture medium increases the adhesiveness to collagen, and decreases the formation of clones in soft agar, demonstrates that the receptor is not fully activated in basal conditions. As LLC-derived tumors displayed expression of CCL20, it is likely that, in vivo as well, the local production of CCL20 results in enhanced adhesion properties of the tumor cells, and a reduction of their metastatic potential. Autocrine/paracrine loops involving CCR6 and CCL20 have also been postulated to underlie the retention of Langerhans cells in histiocytosis lesions. 35 As a conclusion, expression of CCR6 in the LLC cell line significantly decreases the number of metastases in immunocompetent C57BL/6 mice, without affecting the local tumor growth or modifying the metastatic sites. CCR6 can therefore act as a tumor suppressor gene when stimulated in the primary tumor environment. In light of the description of other chemokine receptors (CXCR4 and CCR7) as being able to modify the predominant metastatic sites of tumors, we propose a model in which chemokine receptors expressed in tumor cells can act in two opposite directions according to the local tumor environment. When the cognate ligand is not expressed in the tumor, the receptor will drive the cells to sites in which the ligand is produced, as for leukocyte populations. When the ligand is generated in the tumor itself, the receptor would tend to keep the tumor cells in their primary location, by increasing their local interaction with the extracellular matrix, mimicking the arrest of leukocytes at sites of high chemokine production. The metastatic pathways followed by tumor cells would in this model come one step closer to the physiological trafficking mechanisms of leukocytes through the various compartments of the body. 
